What is Qualio?
Founded in 2012, Qualio offers a cloud-based quality management system designed to help teams launching and scaling life-saving products. Its software is utilized by leading pharmaceutical, biotech, medical device, and clinical research organizations to centralize their processes and data. Qualio's platform is engineered to enable customers to meet stringent regulatory compliance requirements without compromising speed, thereby facilitating the delivery of high-quality products in highly regulated industries. The company operates within the enterprise software and B2B SaaS sectors, focusing on solutions that enhance operational efficiency and compliance.
How much funding has Qualio raised?
Qualio has raised a total of $61M across 2 funding rounds:
Series A
$11M
Series B
$50M
Series A (2020): $11M with participation from Sorenson Capital, Storm Ventures, MHS Capital, Operator Partners, and Frontline Ventures
Series B (2021): $50M led by MHS Capital, Operator Partners, Frontline Ventures, Sorenson Ventures, Tiger Global Management, Storm Ventures, and Menlo Ventures
Key Investors in Qualio
MHS Capital
MHS Capital is an investment firm that partners with entrepreneurs building disruptive technology companies, emphasizing a relationship-focused philosophy and making fewer, bigger bets on visionary entrepreneurs. They aim to be smart money, providing mentorship and strategic support.
Frontline Ventures
Frontline Ventures is a venture firm focused on globally ambitious B2B businesses, with funds dedicated to early-stage companies and US-to-Europe expansion. They have a track record of backing B2B entrepreneurs and achieving successful exits.
Storm Ventures
Storm Ventures is an early-stage venture capital firm specializing in B2B software startups, including AI, enterprise infrastructure, and cybersecurity. They focus on unlocking growth for innovative companies and building a community of founders and partners.
What's next for Qualio?
The substantial enterprise-level funding and recent strategic investment indicate that Qualio is poised for accelerated expansion and product development. This capital infusion is likely to be directed towards enhancing its platform capabilities, broadening its market reach, and potentially exploring new verticals within the life sciences ecosystem. The company's focus on regulatory compliance and speed positions it favorably to capitalize on the increasing demand for robust quality management solutions in industries facing evolving compliance landscapes. Future growth may involve strategic partnerships, further technological innovation, and scaling its go-to-market strategies to capture a larger share of the global market.
See full Qualio company page
